Avtor/Urednik		Černelč, Peter; Kodre, Veronika
Naslov		Ocena učinkovitosti prvega zdravljenja z bortezomibom pred avtologno presaditvijo krvotvornih matičnih celic pri diseminiranem plazmocitomu
Prevedeni naslov		Effectiveness of first treatment with bortezomib prior to autologous stem cell transplantation for multiple myeloma
Tip		članek
Vir		Zdrav Vestn
Vol. in št.		Letnik 81, št. 4
Leto izdaje		2012
Obseg		str. 304-11
Jezik		slo
Abstrakt		Background: In this retrospective study we evaluated effectiveness and safety of first- line treatment with bortezomib and dexamethasone in multiple myeloma patients, comparing our results with already published clinical studies. Methods: Patients received bortezomib as part of everyday clinical practice and according to the latest guidelines of the Združenje hematologov Slovenije . Patients who were previously treated with first-line VAD (vincristine, doxorubicin modified with farmarubicine, dexamethasone), but due to uneffectiveness changed the treatment to bortezomib, were also included in the study. In 30 patients effectivenes was evaluated after average 3-4 cycles of bortezomib and dexamethasone according to the modified Southwest Oncology Group criteria. Treatment effectiveness was evaluated according to the previous VAD treatment, renal function and cytogenetic analysis. Side effects and reasons for early treatment discontinuation were described. Results: Patients received 2 to 8 cycles (median 4 cycles) of bortezomib and dexamethasone treatment. After average 3-4 cycles, 80% of patients acheived good treatment response (56.7% very good partial response, 23.3% partial response). We observed that the treatment, renal insufficiency and negative cytogenetic analysis, sionce we observed similar rates of very good partial response ande partial response in patients without previous VAD treatment (82.3% vs. 76.9%), normal renal function (85.7% vs. 75%) and normal cytogenetics (77.8% vs. 80%), although statistical evaluation was not possible due to small number of patients. The most common side effect was neuropathy (40%) and in 5 patients (16.6%), due to grade 3 or more, the treatment was discontinued. Other side effects were: anemia (26%), infection (166%), thrombocytopenia (10%), neutropenia (6.6%), gastrointestinal problems (23.3%) and herpes zooster (6.6%). (Abstract truncated at 2000 characters).
Deskriptorji		MULTIPLE MYELOMA DEXAMETHASONE ANTIBODIES, MONOCLONAL BENCE JONES PROTEIN PROTEINURIA KIDNEY FAILURE HEMATOPOIETIC STEM CELL TRANSPLANTATION TREATMENT OUTCOME RETROSPECTIVE STUDIES